Aim. To study quality of life (QL) of patients with chronic heart failure (CHF) and QL changes resultant from mildronate therapy. Materials and methods. QL was studied in 30 IHD patients with CHF of NYHA class II-IV, ejection fraction > 45%; 40 IHD patients without CHF and 30 healthy subjects. CHF patients were treated for 30 days with oral mildronate (250mg 4 times a day). QL was assessed according to the method SF-36 Health Status Survey. Results. QL in CHF patients is much lower than that of the controls. Objective severity of the disease and subjective satisfaction with life do not always coincide. Mildronate in a dose 1 g/day per os may be beneficial for LQ of CHF patients. Conclusion. It is thought desirable to include QL in analysis of efficiency of managing parents with CHF. SF-36 is a tool able to follow up changes in QL of CHF patients within a short-term treatment period.